Medical Condition News

RSS

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Idera Pharmaceuticals today provides an update on the clinical development of IMO-2055 (EMD 1201081), a TLR9 agonist for cancer treatment being developed by Merck KGaA, Darmstadt, Germany, under its collaboration with Idera.

8 Jul 2011

Study finds higher rate of switching from Byetta to Victoza in treatment of type 2 diabetes

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although Amylin/Eli Lilly's Byetta currently commands a higher patient share than Novo Nordisk's Victoza, more patients were switched from Byetta to Victoza than vice versa (25.2 percent versus 2.8 percent) in the last quarter of 2010 among recently treated type 2 diabetes patients.

8 Jul 2011

New human syndrome features craniosynostosis, maxillary hyperplasia, delayed tooth eruption, extra teeth

Researchers at the University of Helsinki, Finland, have described a new, recessively inherited human syndrome featuring craniosynostosis, maxillary hyperplasia, delayed tooth eruption and extra teeth. The researchers also identified causative mutations in a gene IL11RA.

8 Jul 2011

Pediatricians debunk pearls of medical wisdom

Don't Cross Your Eyes-They'll Get Stuck that Way!, a new book by myth-fighting Indiana University School of Medicine pediatricians Aaron Carroll, M.D., M.S., and Rachel Vreeman, M.D., M.S., debunks the pearls of medical wisdom that many people and even their physicians believe are true. Be prepared to revise your thinking; no, an apple a day won't keep the doctor away and no, warm milk won't help you sleep.

8 Jul 2011

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.

8 Jul 2011

Autologous adult stem cells reduce frequency of angina episodes

New research published online today in Circulation Research found that injections of adult patients' own CD34+ stem cells reduced reports of angina episodes and improved exercise tolerance time in patients with chronic, severe refractory angina (severe chest discomfort that did not respond to other therapeutic options).

From Baxter International Inc. 8 Jul 2011

New strategy may combat age-associated infertility and birth defects

A strategy that has been shown to reduce age-related health problems in several animal studies may also combat a major cause of age-associated infertility and birth defects.

8 Jul 2011

New target could halt growth of glioblastoma

Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer.

8 Jul 2011

Cardiac Science's Powerheart G3 AED receives Japanese regulatory approval

Cardiac Science Corporation, a global leader in automated external defibrillators (AEDs) and diagnostic cardiac monitoring devices, announced today that the Japan Ministry of Health, Labor, and Welfare approved a new model of its Powerheart G3 AED. The company is partnering with Omron Healthcare to distribute its AEDs in Japan. Japan-based Omron is a leading healthcare company dedicated to prevention of heart disease.

8 Jul 2011

ACMG presents new guideline on genetic counseling, testing for AD

When is it appropriate to perform genetic testing for Alzheimer disease, and what information do patients need to understand their risk? The June issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics presents a new practice guideline on genetic counseling and testing for AD.

8 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

Scientists discover way to separate neural wheat from the chaff

University of Florida scientists have discovered a way to separate the neural wheat from the chaff during the process of generating brain cells for potential patient therapies.

8 Jul 2011

NUS, NTU students win WFF's Ph.D. Prizes for environmental research

Antibiotics, which are among the world's most widely prescribed medicines, can easily find their way into rivers and lakes because they tend not to be removed through the normal sewage process.

8 Jul 2011

New advances in Alzheimer's disease research

Advancing age is a major risk factor for Alzheimer's disease and is associated with build- up of the peptide amyloid β in the brain. New research published in BioMed Central's open access journal Fluids and Barriers of the CNS shows that removal of amyloid β from the brain depends on vitamin D and also on an age-related alteration in the production of transporter proteins which move amyloid β in and out of the brain.

8 Jul 2011

AHAF awards 22 new grants to scientists worldwide for innovative vision research

The American Health Assistance Foundation (AHAF), a nonprofit organization with a history of funding cutting-edge research on age-related diseases, announced today that it has awarded 22 new grants totaling nearly $2.2 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible vision loss and blindness in the U.S.

8 Jul 2011

InVivo files biopolymer scaffold IDE with FDA to initiate spinal cord injury clinical trial

InVivo Therapeutics today announced that the Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for a proprietary biopolymer scaffolding device to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.

8 Jul 2011

Cortisol hormone controls bile acid recycling process

Nature sees to it that we do not have "too much choler" in our body. A delicately equilibrated regulation system ensures that there is always exactly the right amount of bile in the gallbladder. When we are hungry, our body releases a hormone called cortisol, which is a glucocorticoid. Hepatic cells receive this hormone signal through their cortisol receptors and respond by filling the gallbladder with bile in preparation of the imminent food intake.

8 Jul 2011